Peroxisome proliferator-activated receptor-γ agonists suppress iNOS expression induced by LPS in rat primary Schwann cells

Journal of Neuroimmunology

Volumn 218, Issue 1-2, 2010, Pages 36-47

  Zhang, Fupeng ^a   Liu, Fen ^b   Yan, Meijuan ^c   Ji, Huoyan ^a   Hu, Ling ^a   Li, Xiaohong ^a   Qian, Ji ^a   He, Xingxin ^a   Zhang, Li ^a   Shen, Aiguo ^c   Cheng, Chun ^a  

^a Nanlong Medical College   (China)

^b Medical College   (China)

^c NANTONG UNIVERSITY   (China)

Author keywords

Inflammation; Lipopolysaccharide; Mitogen activated protein kinase; Peroxisome proliferators activated receptor (PPAR ); Schwann cell (SC)

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL NUCLEUS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME SYNTHESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR DOWN REGULATION; RNA SEQUENCE; SCHWANN CELL;

ANILIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELL LINE; DOWN-REGULATION; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; LIPOPOLYSACCHARIDES; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; PROSTAGLANDIN D2; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHWANN CELLS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TOLL-LIKE RECEPTOR 4;

EID: 73149083238     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.10.016     Document Type: Article

References (72)

1. Akahori T., Sho M., Hamada K., Suzaki Y., Kuzumoto Y., Nomi T., Nakamura S., Enomoto K., Kanehiro H., and Nakajima Y. Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. J. Hepatol. 47 (2007) 784-792
2. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
3. Anon, 1999. A unified nomenclature system for the nuclear receptor superfamily. Cell 97, 161-163.
4. Aouadi M., Laurent K., Prot M., Le Marchand-Brustel Y., Binetruy B., and Bost F. Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages. Diabetes 55 (2006) 281-289
5. Armati P.J., and Pollard J.D. Immunology of the Schwann cell. Baillieres Clin. Neurol. 5 (1996) 47-64
6. Bae J.H., Jang B.C., Suh S.I., Ha E., Baik H.H., Kim S.S., Lee M.Y., and Shin D.H. Manganese induces inducible nitric oxide synthase (iNOS) expression via activation of both MAP kinase and PI3K/Akt pathways in BV2 microglial cells. Neurosci. Lett. 398 (2006) 151-154
7. Belvisi M.G., and Hele D.J. Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest 134 (2008) 152-157
8. Berger J., Patel H.V., Woods J., Hayes N.S., Parent S.A., Clemas J., Leibowitz M.D., Elbrecht A., Rachubinski R.A., Capone J.P., and Moller D.E. A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Mol. Cell. Endocrinol. 162 (2000) 57-67
9. Beutler B., Hoebe K., Du X., and Ulevitch R.J. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 74 (2003) 479-485
10. Bhatheja K., and Field J. Schwann cells: origins and role in axonal maintenance and regeneration. Int. J. Biochem. Cell Biol. 38 (2006) 1995-1999
11. Brockes J.P., Fields K.L., and Raff M.C. Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res. 165 (1979) 105-118
12. Burgermeister E., and Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 6 (2007) 1539-1548
13. Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M., and Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol. Cell. Biol. 27 (2007) 803-817
14. Cary S.P., Winger J.A., Derbyshire E.R., and Marletta M.A. Nitric oxide signaling: no longer simply on or off. Trends Biochem. Sci. 31 (2006) 231-239
15. Cheng C., Qin Y., Shao X., Wang H., Gao Y., Cheng M., and Shen A. Induction of TNF-alpha by LPS in Schwann cell is regulated by MAPK activation signals. Cell. Mol. Neurobiol. 27 (2007) 909-921
16. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., and Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20 (2000) 558-567
17. Constantin G., Piccio L., Bussini S., Pizzuti A., Scarpini E., Baron P., Conti G., Pizzul S., and Scarlato G. Induction of adhesion molecules on human schwann cells by proinflammatory cytokines, an immunofluorescence study. J. Neurol. Sci. 170 (1999) 124-130
18. Conti G., Rostami A., Scarpini E., Baron P., Galimberti D., Bresolin N., Contri M., Palumbo C., and De Pol A. Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. Exp. Neurol. 187 (2004) 350-358
19. Czlonkowska A., Ciesielska A., Gromadzka G., and Kurkowska-Jastrzebska I. Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. Curr. Pharm. Des. 11 (2005) 1017-1030
20. Da Silva J., Pierrat B., Mary J.L., and Lesslauer W. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes. J. Biol. Chem. 272 (1997) 28373-28380
21. Diradourian C., Girard J., and Pegorier J.P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie. 87 (2005) 33-38
22. Escher P., and Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 448 (2000) 121-138
23. Fahmi H., Di Battista J.A., Pelletier J.P., Mineau F., Ranger P., and Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum. 44 (2001) 595-607
24. Feige J.N., Gelman L., Michalik L., Desvergne B., and Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 45 (2006) 120-159
25. Gold R., Zielasek J., Kiefer R., Toyka K.V., and Hartung H.P. Secretion of nitrite by Schwann cells and its effect on T-cell activation in vitro. Cell. Immunol. 168 (1996) 69-77
26. Gurnell M. PPARgamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol (Oxf) 59 (2003) 267-277
27. Gurnell M., Wentworth J.M., Agostini M., Adams M., Collingwood T.N., Provenzano C., Browne P.O., Rajanayagam O., Burris T.P., Schwabe J.W., Lazar M.A., and Chatterjee V.K. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J. Biol. Chem. 275 (2000) 5754-5759
28. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., and Landreth G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
29. Hoefen R.J., and Berk B.C. The role of MAP kinases in endothelial activation. Vascul. Pharmacol. 38 (2002) 271-273
30. Houseknecht K.L., Cole B.M., and Steele P.J. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest. Anim. Endocrinol. 22 (2002) 1-23
31. Ji Y., Liu J., Wang Z., Liu N., and Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab. Invest. 89 (2009) 887-902
32. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
33. Jiang Z., Georgel P., Du X., Shamel L., Sovath S., Mudd S., Huber M., Kalis C., Keck S., Galanos C., Freudenberg M., and Beutler B. CD14 is required for MyD88-independent LPS signaling. Nat. Immunol. 6 (2005) 565-570
34. Kaisho T., and Akira S. Pleiotropic function of Toll-like receptors. Microbes. Infect. 6 (2004) 1388-1394
35. Kampa M., and Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. Mol. Cell. Endocrinol. 246 (2006) 76-82
36. Kielian T., McMahon M., Bearden E.D., Baldwin A.C., Drew P.D., and Esen N. S. aureus-dependent microglial activation is selectively attenuated by the cyclopentenone prostaglandin 15-deoxy-Delta12, 14-prostaglandin J2 (15d-PGJ2). J. Neurochem. 90 (2004) 1163-1172
37. Kim S.H., Kim J., and Sharma R.P. Inhibition of p38 and ERK MAP kinases blocks endotoxin-induced nitric oxide production and differentially modulates cytokine expression. Pharmacol. Res. 49 (2004) 433-439
38. Kitamura Y., Shimohama S., Koike H., Kakimura J., Matsuoka Y., Nomura Y., Gebicke-Haerter P.J., and Taniguchi T. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254 (1999) 582-586
39. Konukoglu D., Serin O., and Turhan M.S. Plasma leptin and its relationship with lipid peroxidation and nitric oxide in obese female patients with or without hypertension. Arch. Med. Res. 37 (2006) 602-606
40. Levy D., Hoke A., and Zochodne D.W. Local expression of inducible nitric oxide synthase in an animal model of neuropathic pain. Neurosci. Lett. 260 (1999) 207-209
41. Lisak R.P., Skundric D., Bealmear B., and Ragheb S. The role of cytokines in Schwann cell damage, protection, and repair. J. Infect. Dis. 176 Suppl 2 (1997) S173-S179
42. Luo G., Peng D., Zheng J., Chen X., Wu J., Elster E., and Tadaki D. The role of NO in macrophage dysfunction at early stage after burn injury. Burns 31 (2005) 138-144
43. Maeda T., Kiguchi N., Kobayashi Y., Ozaki M., and Kishioka S. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 108 (2008) 341-347
44. Marriott H.M., Ali F., Read R.C., Mitchell T.J., Whyte M.K., and Dockrell D.H. Nitric oxide levels regulate macrophage commitment to apoptosis or necrosis during pneumococcal infection. FASEB J. 18 (2004) 1126-1128
45. Morrison S.G., and Morrison R.P. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J. Immunol. 175 (2005) 7536-7542
46. Nagai H., Kumamoto H., Fukuda M., and Takahashi T. Inducible nitric oxide synthase and apoptosis-related factors in the synovial tissues of temporomandibular joints with internal derangement and osteoarthritis. J. Oral Maxillofac. Surg. 61 (2003) 801-807
47. Nagareddy P.R., Xia Z., MacLeod K.M., and McNeill J.H. N-acetylcysteine prevents nitrosative stress-associated depression of blood pressure and heart rate in streptozotocin diabetic rats. J. Cardiovasc. Pharmacol. 47 (2006) 513-520
48. Orlikowski D., Chazaud B., Plonquet A., Poron F., Sharshar T., Maison P., Raphael J.C., Gherardi R.K., and Creange A. Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barre syndrome and experimental autoimmune neuritis. J. Neuroimmunol. 134 (2003) 118-127
49. Pacurari M., Yin X.J., Zhao J., Ding M., Leonard S.S., Schwegler-Berry D., Ducatman B.S., Sbarra D., Hoover M.D., Castranova V., and Vallyathan V. Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells. Environ. Health Perspect. 116 (2008) 1211-1217
50. Pershadsingh H.A., Heneka M.T., Saini R., Amin N.M., Broeske D.J., and Feinstein D.L. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J. Neuroinflammation 1 (2004) 3
51. Petrova T.V., Akama K.T., and Van Eldik L.J. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12, 14-prostaglandin J2. Proc. Natl. Acad. Sci. USA 96 (1999) 4668-4673
52. Phulwani N.K., Feinstein D.L., Gavrilyuk V., Akar C., and Kielian T. 15-deoxy-Delta12, 14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway. J. Neurochem. 99 (2006) 1389-1402
53. Qin Y., Cheng C., Wang H., Shao X., Gao Y., and Shen A. TNF-alpha as an autocrine mediator and its role in the activation of Schwann cells. Neurochem. Res. 33 (2008) 1077-1084
54. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
55. Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell. Signal. 15 (2003) 355-366
56. Saraiva R.M., and Hare J.M. Nitric oxide signaling in the cardiovascular system: implications for heart failure. Curr. Opin. Cardiol. 21 (2006) 221-228
57. Shen A., Yang J., Gu Y., Zhou D., Sun L., Qin Y., Chen J., Wang P., Xiao F., Zhang L., and Cheng C. Lipopolysaccharide-evoked activation of p38 and JNK leads to an increase in ICAM-1 expression in Schwann cells of sciatic nerves. FEBS J. 275 (2008) 4343-4353
58. Shibuya A., Wada K., Nakajima A., Saeki M., Katayama K., Mayumi T., Kadowaki T., Niwa H., and Kamisaki Y. Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett. 525 (2002) 43-47
59. Storling J., Binzer J., Andersson A.K., Zullig R.A., Tonnesen M., Lehmann R., Spinas G.A., Sandler S., Billestrup N., and Mandrup-Poulsen T. Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 48 (2005) 2039-2050
60. Sung B., Park S., Yu B.P., and Chung H.Y. Modulation of PPAR in aging, inflammation, and calorie restriction. J. Gerontol. A Biol. Sci. Med. Sci. 59 (2004) 997-1006
61. Tinker A.C., and Wallace A.V. Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases?. Curr. Top Med. Chem. 6 (2006) 77-92
62. Tofaris G.K., Patterson P.H., Jessen K.R., and Mirsky R. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J. Neurosci. 22 (2002) 6696-6703
63. Tureyen K., Kapadia R., Bowen K.K., Satriotomo I., Liang J., Feinstein D.L., and Vemuganti R. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 101 (2007) 41-56
64. Ulett G.C., and Adderson E.E. Nitric oxide is a key determinant of group B streptococcus-induced murine macrophage apoptosis. J. Infect. Dis. 191 (2005) 1761-1770
65. Vidal-Puig A., Jimenez-Linan M., Lowell B.B., Hamann A., Hu E., Spiegelman B., Flier J.S., and Moller D.E. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97 (1996) 2553-2561
66. Vougioukas V.I., Roeske S., and Bruck W. Involvement of intercellular adhesion molecule-1 in myelin recognition by macrophages. Acta Neuropathol. 99 (2000) 673-679
67. Vunta H., Davis F., Palempalli U.D., Bhat D., Arner R.J., Thompson J.T., Peterson D.G., Reddy C.C., and Prabhu K.S. The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12, 14-prostaglandin J2 in macrophages. J. Biol. Chem. 282 (2007) 17964-17973
68. Wang H., Cheng C., Qin Y., Niu S., Gao S., Li X., Tao T., and Shen A. Role of mitogen-activated protein kinase cascades in inducible nitric oxide synthase expression by lipopolysaccharide in a rat schwann cell line. Neurochem. Res. 34 (2009) 430-437
69. Xu J., and Drew P.D. Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J. Immunol. 178 (2007) 1904-1913
70. Xu Z., Wang B.R., Wang X., Kuang F., Duan X.L., Jiao X.Y., and Ju G. ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury. Life Sci. 79 (2006) 1895-1905
71. Yamagishi S., Ogasawara S., Mizukami H., Yajima N., Wada R., Sugawara A., and Yagihashi S. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J. Neurochem. 104 (2008) 491-499
72. Zhao Y., Fei M., Wang Y., Lu M., Cheng C., and Shen A. Expression of Foxo3a in non-Hodgkin's lymphomas is correlated with cell cycle inhibitor p27. Eur. J. Haematol. 81 (2008) 83-93